Immunoglobulin G1-Kappa, Anti-[Homo Sapiens Klrb1 (Killer Cell Lectin Like Receptor B1, Nkr-P1A, Natural Killer Cell Surface Protein P1A, Clec5B, Cd161)], Homo Sapiens Monoclonal Antibody; Gamma1 Heavy Chain Homo Sapiens (1-450) [Vh (Homo Sapiens Ighv3-23*01 (96.9%) -(Ighd) -Ighj4*01 (85.7%), Q120>R (113), Cdr-Imgt [8.8.14] (26-33.51-58.97-110)) (1-121) -Homo Sapiens Ighg1*01, G1M17,1 Ch1 K120, Ch3 D12, L14, G1V29 Ch2 A84.4 (Ch1 K120 (218) (122-219), Hinge 1-15 (220-234), Ch2 G1V29 Ch2 N84.4>A (301) (235-344), Ch3 D12 (360), L14 (362) (345-449), Chs K2>Del (450)) (122-450)], (224-214')-Disulfide With Kappa Light Chain Homo Sapiens (1'-214') [V-Kappa (Homo Sapiens Igkv1-12*01 (94.7%) -Igkj4*01 (91.7%), Cdr-Imgt [6.3.9] (27'-32'.50'-52'.89'-97')) (1'-107') -Homo Sapiens Igkc*01 (100%), Km3, A45.1 (153'), V101 (191') (108'-214')]; Dimer (230-230'':233-233'')-Bisdisulfide, Produced In Chinese Hamster Ovary (Cho) Cells, Cell Line Cho-K1 Lacking The Glutamine Synthetase (Gs-Ko) Gene, Non-Glycosylated
Hodgkins Lymphoma
Explore 141 assets in Hodgkins Lymphoma →Floatz Rating
CC41/100
Confidence
Indicative
Sponsor
Immunitas Therapeutics
Modality
monoclonal_antibody
Development Phase
Phase 1/2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
33Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05565417CT.gov Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Hodgkins Lymphoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Immunoglobulin G1-Kappa, Anti-[Homo Sapiens Klrb1 (Killer Cell Lectin Like Receptor B1, Nkr-P1A, Natural Killer Cell Surface Protein P1A, Clec5B, Cd161)], Homo Sapiens Monoclonal Antibody; Gamma1 Heavy Chain Homo Sapiens (1-450) [Vh (Homo Sapiens Ighv3-23*01 (96.9%) -(Ighd) -Ighj4*01 (85.7%), Q120>R (113), Cdr-Imgt [8.8.14] (26-33.51-58.97-110)) (1-121) -Homo Sapiens Ighg1*01, G1M17,1 Ch1 K120, Ch3 D12, L14, G1V29 Ch2 A84.4 (Ch1 K120 (218) (122-219), Hinge 1-15 (220-234), Ch2 G1V29 Ch2 N84.4>A (301) (235-344), Ch3 D12 (360), L14 (362) (345-449), Chs K2>Del (450)) (122-450)], (224-214')-Disulfide With Kappa Light Chain Homo Sapiens (1'-214') [V-Kappa (Homo Sapiens Igkv1-12*01 (94.7%) -Igkj4*01 (91.7%), Cdr-Imgt [6.3.9] (27'-32'.50'-52'.89'-97')) (1'-107') -Homo Sapiens Igkc*01 (100%), Km3, A45.1 (153'), V101 (191') (108'-214')]; Dimer (230-230'':233-233'')-Bisdisulfide, Produced In Chinese Hamster Ovary (Cho) Cells, Cell Line Cho-K1 Lacking The Glutamine Synthetase (Gs-Ko) Gene, Non-Glycosylated (this asset) | Immunitas Therapeutics | P1/2 | CC · 41 |
| Camustine | VIVUS LLC | P2 | BBB |
| Everolimus | OHSU Knight Cancer Institute | P2 | BBB |
| Carboplatin | St. Petersburg State Pavlov Medical University | P2 | BBB |
| Isocyclophosphamide | St. Petersburg State Pavlov Medical University | P3 | BBB |
| Cyclosporin A | City of Hope Medical Center | P3 | BBB |
| Irinotecan | OHSU Knight Cancer Institute | P2 | BBB |
| Vincristine Sulfate | National Cancer Institute (NCI) | P3 | BBB |
| Vinblastine | M.D. Anderson Cancer Center | P4 | BBB |
+42 more in the Hodgkins Lymphoma cohort
Other indications for Immunoglobulin G1-Kappa, Anti-[Homo Sapiens Klrb1 (Killer Cell Lectin Like Receptor B1, Nkr-P1A, Natural Killer Cell Surface Protein P1A, Clec5B, Cd161)], Homo Sapiens Monoclonal Antibody; Gamma1 Heavy Chain Homo Sapiens (1-450) [Vh (Homo Sapiens Ighv3-23*01 (96.9%) -(Ighd) -Ighj4*01 (85.7%), Q120>R (113), Cdr-Imgt [8.8.14] (26-33.51-58.97-110)) (1-121) -Homo Sapiens Ighg1*01, G1M17,1 Ch1 K120, Ch3 D12, L14, G1V29 Ch2 A84.4 (Ch1 K120 (218) (122-219), Hinge 1-15 (220-234), Ch2 G1V29 Ch2 N84.4>A (301) (235-344), Ch3 D12 (360), L14 (362) (345-449), Chs K2>Del (450)) (122-450)], (224-214')-Disulfide With Kappa Light Chain Homo Sapiens (1'-214') [V-Kappa (Homo Sapiens Igkv1-12*01 (94.7%) -Igkj4*01 (91.7%), Cdr-Imgt [6.3.9] (27'-32'.50'-52'.89'-97')) (1'-107') -Homo Sapiens Igkc*01 (100%), Km3, A45.1 (153'), V101 (191') (108'-214')]; Dimer (230-230'':233-233'')-Bisdisulfide, Produced In Chinese Hamster Ovary (Cho) Cells, Cell Line Cho-K1 Lacking The Glutamine Synthetase (Gs-Ko) Gene, Non-Glycosylated
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Small Intestine Cancer | — | P1/2 | CCC · 48 |
| Hormone Receptor-Positive Breast Cancer | — | P1/2 | CC · 47 |
| Skin Squamous Cell Carcinoma | — | P1/2 | CC · 45 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Immunoglobulin G1-Kappa, Anti-[Homo Sapiens Klrb1 (Killer Cell Lectin Like Receptor B1, Nkr-P1A, Natural Killer Cell Surface Protein P1A, Clec5B, Cd161)], Homo Sapiens Monoclonal Antibody; Gamma1 Heavy Chain Homo Sapiens (1-450) [Vh (Homo Sapiens Ighv3-23*01 (96.9%) -(Ighd) -Ighj4*01 (85.7%), Q120>R (113), Cdr-Imgt [8.8.14] (26-33.51-58.97-110)) (1-121) -Homo Sapiens Ighg1*01, G1M17,1 Ch1 K120, Ch3 D12, L14, G1V29 Ch2 A84.4 (Ch1 K120 (218) (122-219), Hinge 1-15 (220-234), Ch2 G1V29 Ch2 N84.4>A (301) (235-344), Ch3 D12 (360), L14 (362) (345-449), Chs K2>Del (450)) (122-450)], (224-214')-Disulfide With Kappa Light Chain Homo Sapiens (1'-214') [V-Kappa (Homo Sapiens Igkv1-12*01 (94.7%) -Igkj4*01 (91.7%), Cdr-Imgt [6.3.9] (27'-32'.50'-52'.89'-97')) (1'-107') -Homo Sapiens Igkc*01 (100%), Km3, A45.1 (153'), V101 (191') (108'-214')]; Dimer (230-230'':233-233'')-Bisdisulfide, Produced In Chinese Hamster Ovary (Cho) Cells, Cell Line Cho-K1 Lacking The Glutamine Synthetase (Gs-Ko) Gene, Non-Glycosylated in Hodgkins Lymphoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/immunoglobulin-g1-kappa-anti-homo-sapiens-klrb1-killer-cell-lectin-like-receptor-b1-nkr-p1a-natural-killer-cell-surface-protein-p1a-clec5b-cd161-homo-sapiens-monoclonal-antibody-gamma1-heavy-chain-homo-sapiens-1-450-vh-homo-sapiens-ighv3-2301-969-ighd-ighj401-857-q120r-113-cdr-imgt-8814-26-3351-5897-110-1-121-homo-sapiens-ighg101-g1m171-ch1-k120-ch3-d12-l14-g1v29-ch2-a844-ch1-k120-218-122-219-hinge-1-15-220-234-ch2-g1v29-ch2-n844a-301-235-344-ch3-d12-360-l14-362-345-449-chs-k2del-450-122-450-224-214-disulfide-with-kappa-light-chain-homo-sapiens-1-214-v-kappa-homo-sapiens-igkv1-1201-947-igkj401-917-cdr-imgt-639-27-3250-5289-97-1-107-homo-sapiens-igkc01-100-km3-a451-153-v101-191-108-214-dimer-230-230233-233-bisdisulfide-produced-in-chinese-hamster-ovary-cho-cells-cell-line-cho-k1-lacking-the-glutamine-synthetase-gs-ko-gene-non-glycosylated-hodgkins-lymphoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →